Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of V260 in Healthy Chinese Adults, Children and Infants (V260-028)(COMPLETED)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00953056
Recruitment Status : Completed
First Posted : August 6, 2009
Results First Posted : April 15, 2011
Last Update Posted : November 1, 2015
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study will assess the safety and tolerability of RotaTeq™ (V260) in the healthy Chinese populations. Approximately 144 participants will be enrolled and equally stratified into three age cohorts, Cohort I ages 19-47 years, Cohort II ages 2-6 years, and Cohort III ages 6-12 weeks. Randomization ratio is 1:1 in each cohort. The study will be conducted sequentially, participants in Cohort I then Cohort II receiving 1 dose of, and then participants in Cohort III receiving 3 doses of RotaTeq™/placebo. The primary investigator and the Ethics Review Committee will review blinded safety data and make decision based on their best clinical judgment to move study forward between cohorts. Duration for the entire study will be approximately 6-9 months.

Condition or disease Intervention/treatment Phase
Rotavirus Gastroenteritis Biological: Rotavirus Vaccine, Live, Oral, Pentavalent Biological: Comparator: Placebo Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 144 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Double-Blind, Randomized, Placebo-Controlled, Safety and Tolerability Study of Live Pentavalent Human-Bovine Reassortant Rotavirus Vaccine in Chinese Healthy Adults, Children and Infants
Study Start Date : September 2009
Actual Primary Completion Date : March 2010
Actual Study Completion Date : March 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vaccines

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Cohort I - RotaTeq™, Adults
Adults randomized to receive a single dose of RotaTeq™.
 Biological: Rotavirus Vaccine, Live, Oral, Pentavalent

Single 2.0 mL dose V260 (RotaTeq™) administered orally at enrollment.

The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses.

Other Name: V260, RotaTeq™
Placebo Comparator: Cohort I - Placebo, Adults
Adults randomized to receive a single dose of matching placebo to RotaTeq™.
 Biological: Comparator: Placebo
Single 2.0 mL dose of matching placebo to RotaTeq™ administered orally at enrollment.
Experimental: Cohort II - RotaTeq™, Children
Children randomized to receive a single dose of RotaTeq™.
 Biological: Rotavirus Vaccine, Live, Oral, Pentavalent

Single 2.0 mL dose V260 (RotaTeq™) administered orally at enrollment.

The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses.

Other Name: V260, RotaTeq™
Placebo Comparator: Cohort II - Placebo, Children
Children randomized to receive a single dose of matching placebo to RotaTeq™.
 Biological: Comparator: Placebo
Single 2.0 mL dose of matching placebo to RotaTeq™ administered orally at enrollment.
Experimental: Cohort III - RotaTeq™, Infants
Infants randomized to receive 3 doses of RotaTeq™.
 Biological: Rotavirus Vaccine, Live, Oral, Pentavalent

Three 2.0 mL doses of RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.

The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses.

Other Name: V260, RotaTeq™.
Placebo Comparator: Cohort III - Placebo, Infants
Infants randomized to receive 3 doses of matching placebo to RotaTeq™.
 Biological: Comparator: Placebo
Three 2.0 mL doses of matching placebo to RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of Participants With Serious Adverse Events [ Time Frame: up to 14 days post vaccination ]
    All serious adverse events (SAEs) were collected for 14 days following each dose to obtain the number of participants with serious adverse events.

  2. Number of Serious Adverse Events [ Time Frame: 14 days post vaccination ]
    The total number of serious adverse experiences (events) in participants up to 14 days post vaccination.


Secondary Outcome Measures :
  1. Number of Infants With Fecal Vaccine Virus Shedding [ Time Frame: Between Day 3 and Day 7 following each of 3 doses of RotaTeq™/placebo ]
    Fecal shedding of vaccine rotavirus in Cohort III (infants) was evaluated by determining the number of participants whose stool was positive by both (1) the Enzyme-linked Immunosorbent Assay (EIA) to detect the rotavirus antigen, and (2) PCR VP6 Genotyping (a polymerase chain reaction assay specific for rotavirus genome 6, coding for the VP6 protein of the vaccine virus). For analysis, two stool samples were collected per participant on separate days between Day 3 and Day 7 following each vaccination dose.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Weeks to 47 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adults ages 19 to 47 years for Cohort I
  • Healthy children ages 2 to 6 years for Cohort II
  • Healthy infants ages 6 to 12 weeks for Cohort III
  • Negative pregnancy test for females in Cohort I
  • Signed Informed Consent Forms (ICFs)

Exclusion Criteria:

  • Participants in Cohorts I and II receiving any vaccine 14 days before or anticipated after study vaccine
  • Participants in Cohort III receiving non-concomitant live vaccines 14 days before or after study vaccine
  • Prior administration of any rotavirus vaccine
  • Elevated temperature, with axillary temperature ≥37.1 Degrees C 24 hours before study vaccine
  • Prior or active gastrointestinal illnesses, immunodeficiency
  • Any condition which may interfere with evaluation of study objectives or make participation in the study unsafe for the participant
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00953056


Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00953056    
Other Study ID Numbers: V260-028
2009_627
First Posted: August 6, 2009    Key Record Dates
Results First Posted: April 15, 2011
Last Update Posted: November 1, 2015
Last Verified: October 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
 Vaccines
Immunologic Factors
Physiological Effects of Drugs